They offer us clues about 2022.Moderna's (NASDAQ: MRNA) transformation from a clinical-stage biotech company to a commercial-stage one has been rapid -- and impressive. Only a year ago, Moderna didn't even have products on the market. And now, in its first full quarter of sales, the company's ...

https://www.fool.com/investing/2021/05/12/here-are-the-3-most-important-numbers-in-modernas/?source=iedfolrf0000001

#fool